Temozolomide is used widely to treat malignant glioma but the overall response to this agent is generally poor. Resistance to DNA damaging drugs such as temozolomide have been related to the induction of anti-apoptotic proteins. Specifically, the transcription factor NF-kappaB has been suggested to participate in promoting the survival of cells exposed to chemotherapy. To identify factors that modulate cytotoxicity in the setting of DNA damage, we used an unbiased strategy to examine the NF-κB-dependent expression profile induced by temozolomide. By this route, we defined the decoy receptor DcR1 as a temozolomide response gene induced by a mechanism relying upon p50/NF-kappaB1. A conserved NF-kappaB binding sequence (κB-site) was identified in the proximal promoter and demonstrated to be required for DcR1 induction by temozolomide. Loss-of-function and gain-of-function studies revealed that the atypical IkappaB protein, Bcl3, was also required for induction of DcR1 by temozolomide. Mechanistically, DcR1 attenuated temozolomide efficacy by blunting activation of the Fas receptor pathway in p53+/+ glioma cells. Intracranial xenograft studies showed that that DcR1 depletion in glioma cells enhanced the efficacy of temozolomide. Taken together, our results showed how DcR1 upregulation mediates temozolomide resistance, and provided a rationale for DcR1 targeting as a strategy to sensitize gliomas to this widely used chemotherapy.


